Your session is about to expire
← Back to Search
Other
Cicletanine 150 mg BID for Pulmonary Arterial Hypertension
Phase 2
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week placebo-controlled treatment period, and a long-term, blinded extension period.
Eligible Conditions
- Pulmonary Arterial Hypertension
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Cicletanine 300 mg QDExperimental Treatment1 Intervention
Cicletanine 300 mg administered once daily (QD)
Group II: Cicletanine 150 mg QDExperimental Treatment1 Intervention
Cicletanine 150 mg administered once daily (QD)
Group III: Cicletanine 150 mg BIDExperimental Treatment1 Intervention
Cicletanine 150 mg administered twice daily (BID)
Group IV: PlaceboPlacebo Group2 Interventions
Placebo to match cicletanine administered once daily
Find a Location
Who is running the clinical trial?
Gilead SciencesLead Sponsor
1,134 Previous Clinical Trials
867,797 Total Patients Enrolled
15 Trials studying Pulmonary Arterial Hypertension
2,767 Patients Enrolled for Pulmonary Arterial Hypertension
Gennyne Walker, PhDStudy ChairSenior Clinical Research Scientist, Gilead Sciences
Share this study with friends
Copy Link
Messenger